BioNTech (NASDAQ:BNTX – Get Free Report) had its price objective lowered by analysts at HC Wainwright from $145.00 to $138.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 31.47% from the stock’s previous close. HC Wainwright also issued estimates for BioNTech’s Q4 2026 earnings at $0.88 EPS.
BNTX has been the topic of several other reports. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday, June 7th. Citigroup reiterated a “buy” rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a report on Thursday, May 22nd. Canaccord Genuity Group restated a “buy” rating and set a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Finally, The Goldman Sachs Group began coverage on BioNTech in a research note on Thursday, May 29th. They set a “neutral” rating and a $110.00 target price for the company. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.86.
Check Out Our Latest Analysis on BioNTech
BioNTech Trading Down 1.3%
Hedge Funds Weigh In On BioNTech
Large investors have recently bought and sold shares of the business. Daiwa Securities Group Inc. raised its holdings in shares of BioNTech by 7.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after buying an additional 128 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares during the last quarter. Probity Advisors Inc. raised its holdings in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after buying an additional 154 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of BioNTech by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock valued at $227,000 after buying an additional 209 shares during the last quarter. Finally, Midwest Professional Planners LTD. raised its holdings in shares of BioNTech by 5.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after buying an additional 222 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
- Five stocks we like better than BioNTech
- Short Selling – The Pros and Cons
- Analyst Downgrades Joby, But Overlooks Major Regulatory Wins
- The Risks of Owning Bonds
- U.S. Steel Stock Burns the Bears With Surprise Upside Move
- Insider Trades May Not Tell You What You Think
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.